Literature DB >> 2025958

Synergistic effect of coumarin (1,2 benzopyrone) and endotoxin in the induction of human interleukin-1.

K Stuhlmeier1, G Theyer, G Baumgartner, G J Zlabinger.   

Abstract

Coumarin as well as its derivatives 7-OH coumarin and 4-OH coumarin were found to stimulate interleukin-1 beta (IL-1 beta) release from freshly isolated human mononuclear cells (MNC) if the culture medium contained fetal calf serum. Under serum-free conditions, almost no induction of IL-1 beta release was observed and the former effect could be completely eliminated by polymyxin B. Therefore, the combined action of endotoxin and coumarin was tested on MNC IL-1 beta production. The coumarins were able to potentiate human MNC IL-1 beta production by lipopolysaccharide (LPS) in a dose-dependent manner. That the effect was due to the presence of coumarins and not endotoxin contamination was shown by negative Limulus amebocyte lysate tests and pre-incubation of the coumarins with polymyxin B-agarose. The latter procedure was able to block endotoxin induced IL-1 beta production but the synergism between coumarin and endotoxin was not influenced by pre-incubating the coumarins with polymyxin B-agarose. Cycloheximide as well as actinomycin D eliminated the induction of IL-1 release by coumarin and LPS demonstrating that the cytokine was newly synthesized after MNC stimulation. In addition, both the total amount of MNC IL-1 beta (cell-associated + extracellular) and the extracellular portion of the cytokine were synergistically decreased if coumarin or its derivatives were added to endotoxin-stimulated cultures. Synergism of coumarin and endotoxin in the induction of interleukin-6 or tumour necrosis factor-alpha could be observed in a smaller percentage of donors. These findings demonstrate an immunomodulatory effect of coumarin on cytokine production by monocytes in vitro which might help to explain some of the biological activities attributed to the drug upon its application in tumour patients.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2025958      PMCID: PMC1535382          DOI: 10.1111/j.1365-2249.1991.tb08167.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  22 in total

1.  Inhibition of chemical carcinogen-induced neoplasia by coumarins and alpha-angelicalactone.

Authors:  L W Wattenberg; L K Lam; A V Fladmoe
Journal:  Cancer Res       Date:  1979-05       Impact factor: 12.701

2.  An in vitro demonstration of proteolysis by macrophages and its increase with coumarin.

Authors:  T Bolton; J R Casley-Smith
Journal:  Experientia       Date:  1975-03-15

3.  Involvement of class II MHC molecules in the LPS-induction of IL-1/TNF secretions by human monocytes. Quantitative differences at the polymorphic level.

Authors:  P Santamaria; R C Gehrz; M K Bryan; J J Barbosa
Journal:  J Immunol       Date:  1989-08-01       Impact factor: 5.422

4.  A study of the mechanism by which anticoagulation with warfarin inhibits blood-borne metastases.

Authors:  J M Brown
Journal:  Cancer Res       Date:  1973-06       Impact factor: 12.701

5.  Cimetidine and coumarin therapy of melanoma.

Authors:  R D Thornes; G Lynch; M V Sheehan
Journal:  Lancet       Date:  1982-08-07       Impact factor: 79.321

6.  Pharmacokinetics of coumarin and its 7-hydroxy-metabolites upon intravenous and peroral administration of coumarin in man.

Authors:  W A Ritschel; M E Brady; H S Tan; K A Hoffmann; I M Yiu; K W Grummich
Journal:  Eur J Clin Pharmacol       Date:  1977-12-28       Impact factor: 2.953

7.  A comparison of coumarin and levamisole on parameters of the inflammatory response.

Authors:  M S Koh; D A Willoughby
Journal:  Agents Actions       Date:  1979-08

8.  Warfarin treatment of mice bearing autochthonous tumors: effect on spontaneous metastases.

Authors:  J J Ryan; A S Ketcham; H Wexler
Journal:  Science       Date:  1968-12-27       Impact factor: 47.728

9.  Potentiation of the T-lymphocyte response to mitogens. I. The responding cell.

Authors:  I Gery; R K Gershon; B H Waksman
Journal:  J Exp Med       Date:  1972-07-01       Impact factor: 14.307

10.  Similarities of the anti-tumour actions of endotoxin, lipid A and double-stranded RNA.

Authors:  I Parr; E Wheeler; P Alexander
Journal:  Br J Cancer       Date:  1973-05       Impact factor: 7.640

View more
  7 in total

1.  Mode of action of coumarin in immune cells.

Authors:  G J Zlabinger; C Nöhammer; G A Böhmig; J E Menzel
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

2.  Antitumour activity of coumarin and 7-hydroxycoumarin against 7,12-dimethylbenz[a]anthracene-induced rat mammary carcinomas.

Authors:  A Maucher; E von Angerer
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

3.  Evaluation of the antitumour activity of coumarin in prostate cancer models.

Authors:  A Maucher; M Kager; E von Angerer
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

4.  Growth-inhibitory effects of coumarin (1,2-benzopyrone) and 7-hydroxycoumarin on human malignant cell lines in vitro.

Authors:  M E Marshall; K Kervin; C Benefield; A Umerani; S Albainy-Jenei; Q Zhao; M B Khazaeli
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

5.  Treatment with coumarin to prevent or delay recurrence of malignant melanoma.

Authors:  R D Thornes; L Daly; G Lynch; B Breslin; H Browne; H Y Browne; T Corrigan; P Daly; G Edwards; E Gaffney
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

6.  The effects of coumarin and suramin on the growth of malignant renal and prostatic cell lines.

Authors:  R B Myers; M Parker; W E Grizzle
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

Review 7.  An updated review of the clinical development of coumarin (1,2-benzopyrone) and 7-hydroxycoumarin.

Authors:  M E Marshall; J L Mohler; K Edmonds; B Williams; K Butler; M Ryles; L Weiss; D Urban; A Bueschen; M Markiewicz
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.